PharmAthene started at Buy


H.C. Wainwright initiates coverage of PhamAthene (PIP) with a Buy rating and $4 price target.

Bullish outlook based mainly on a successful outcome of its litigation with SIGA Technologies over the small pox antiviral product Arestvyr.

Shares currently trade at $1.95.

19 mutual funds have positions, up from 15 a year earlier.

From other sites
Comments (1)
  • docrog123
    , contributor
    Comments (150) | Send Message
     
    will there ever be a settlement for the law case with Siga, or does this go on forever?
    10 Jun 2014, 01:57 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs